Bicycle Therapeutics reports Q4 EPS ($1.16), consensus ($1.23)

Cash and cash equivalents were $526.4M as of December 31, 2023, compared to $339.2M as of December 31, 2022. “2023 was a pivotal year for our company, during which we achieved significant progress across our Nectin-4 and EphA2 clinical oncology portfolios and our discovery pipeline of next-generation Bicycle(R) molecules, including in radiopharmaceuticals and areas beyond oncology. We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients,” said Kevin Lee, CEO of Bicycle Therapeutics. “With a catalyst-rich 2024 expected, a strong financial position, validating partnerships and a unique platform technology, we enter this year with significant momentum and focus to advance our mission to help patients not only live longer but also live well.”